CStone Pharma Approved to Begin US Trial of PD1 Candidate

CStone Pharma Approved to Begin US Trial of PD-1 Candidate

CStone Pharma of Suzhou received permission from US clinical trials of its novel PD-1 mAb, CS1003. One week ago, CStone announced a US approval to start a trial of another immunoncology candidate, its PD-L1 molecule, CS1001. Both candidates are full-length, humanized immunoglobulin G4 (IgG4) mAbs, and both showed good tolerability and efficacy in preclinical studies. In May, CStone began a Phase I trial of the PD-1 candidate in Australia. The Phase I trials will determine the Phase II dose for CS1003 in solid tumor patients. More details....

Share this with colleagues:

Original Article: CStone Pharma Approved to Begin US Trial of PD-1 Candidate

More From BioPortfolio on "CStone Pharma Approved to Begin US Trial of PD-1 Candidate"